
NMR · NYSE
A current consensus rating and analyst count are unavailable in the supplied evidence, so no defensible consensus split can be reported. Target information is inconsistent across sources: Fintel cites forecasts from $5.54 to $8.64, Zacks cites a $6.20 target, and Markets Daily reports a $10.20 average target based on five brokerages. The Markets Daily snippet says one analyst rated Nomura Hold, three rated it Buy, and one rated it Strong Buy, but it does not name the firms, analysts, or individual targets. No analyst revisions during the week beginning August 31, 2026 are identified. The substantive disagreement is therefore the unusually wide target range and conflicting aggregate figures, not a documented change in fundamentals.